Sniffing out the evidence; It’s now time for public health bodies recognize the link between COVID-19 and smell and taste disturbance*

Jerome R. Lechien1,2, Claire Hopkins3,#, Sven Saussez4,#
1 COVID-19 Task Force of the Young-Otolaryngologists of the International Federations of Oto-rhino-laryngological Societies (YO-IFOS)
2 Department of Human Anatomy and Experimental Oncology, Faculty of Medicine, UMONS Research Institute for Health Sciences and Technology, University of Mons (UMons), Mons, Belgium
3 Guy’s and St Thomas NHS Foundation Trust, London, UK
4 Department of Otorhinolaryngology and Head and Neck Surgery, CHU de Bruxelles, CHU Saint-Pierre, School of Medicine, Université Libre de Bruxelles, Brussels, Belgium

Since the outbreak of the pandemic, anecdotal observations have been accumulating rapidly that sudden anosmia and dysgeusia are peculiar symptoms associated with the COVID-19 infection. Prof C. Hopkins, as President of British Rhinological Society, published a letter describing “the loss of sense of smell as a marker of COVID-19 infection” and proposed that adults presenting with anosmia but no other symptoms should self-isolate for seven days. The Hopkins team published the first case report and case series as well as other evidence that isolated sudden onset anosmia (ISOA), should be considered highly suspicious for SARS-CoV-2(1). Subsequently, a larger series of 2428 patients presenting with new onset anosmia during the COVID-19 pandemic has been reported, of whom 16% reported the recognized symptoms of cough or fever. A major limitation of this series however, was a lack of access to testing to confirm the COVID-19 status of the patients(2); in the 80 who had been tested 74% were positive. In the same way, the American Academy of Otolaryngology-head and neck surgery (AAO-HNS) proposed “that anosmia could be added to the list of screening tools for possible COVID-19 infection”. Kaye et al. report on 237 US patients with COVID-19 and anosmia, collated through an AAO-HNS resource, and state that loss of sense of smell was present before diagnosis in 73% of respondents, and was the initial symptom in 26.6%; supporting the suggestion it is a useful early marker to prompt testing or self-isolation. Interestingly, these early reports have suggested a predominance of olfactory dysfunction in younger, female patients; this is in contrast to the general population, where olfactory function has been found to be lower in males an older patients.(3, 4).

Two as yet unpublished studies undergoing peer review have specifically reported on the rate of COVID19 infection in otherwise paucisymptomatic patients with anosmia as the major/only symptom. Lechien et al. (5) found that 87 % of patients tested within 12 days of onset of anosmia had a positive viral load for COVID-19, with viral load decreasing throughout the period from onset of anosmia. Similarly, Salmon et al. have undertaken PCR analysis of nasopharyngeal swabs from 55 patients within 7 days of developing sudden onset anosmia without nasal obstruction; 94% were COVID-19 positive (6).
Subsequent to initial reports suggesting anosmia could be a symptom of COVID-19, loss of sense of smell was added to a symptom tracker app developed by a team at King’s College London, with 1.5 million app users between 24-29 March 2020. Of these, 1,702 reported having been tested for COVID-19, with 579 positive results and 1,123 negative results. 59% of COVID-19 positive patients reported loss of smell and taste, compared with only 18% of those who tested negative. These results were much stronger in predicting a positive COVID-19 diagnosis than self-reported fever. Using all the data collected, the King’s research team developed a model to identify which combination of symptoms together could predict COVID-19 cases which includes a combination of loss of smell and taste, fever, persistent cough, fatigue, diarrhea, abdominal pain and loss of appetite. The strongest predictor is loss of smell and taste. In a similar study, from a single centre in the US, reporting on 59 COVID-19 positive patients, and 203 with negative test results, smell and taste impairment were independently and strongly associated with COVID-19 positivity (OR 10.9 for anosmia and 10.2 for ageusia). Combining these 2 studies, anosmia has a positive predictive value of 61% for COVID19 positivity on PCR testing, sensitivity of 60% and specificity of 81%.

While selection bias likely exists amongst volunteers for online surveys, studies of consecutive cases of COVID-19 positive patients provide similar estimates of prevalence; Spinato et al., interviewing mild-moderate patients, found that 64.6% reported reduction in smell or taste, 75% of whom reported a severe or complete loss. Most recently, the first report of objective testing of olfactory function in a case-matched controlled series of patients with COVID-19 in Iran has been reported; 59 out of 60 patients were found to have olfactory dysfunction, with significantly poorer olfactory function that controls (P<0.0001). The majority of patients were completely anosmic.

There is a known high seasonal variation in presentation in olfactory dysfunction with a peak in March, likely caused by viruses that cause the common cold; caution therefore has been required to avoid incorrect attribution of causation to COVID-19, with the apparent ‘surge’ perhaps simply caused by normal background viral infections, with higher reporting rates being encouraged by media attention. We feel that there is now sufficient evidence to be confident in a casual association.

We believe there is urgent need to add anosmia to the list of symptoms used in screening tools for possible COVID-19 infection. The current and further evolving evidence base makes it untenable to disregard this symptom any longer. France, Switzerland and the US have already adopted these measures, while other public health bodies are yet to acknowledge the link – the World Health Organization noted the early reports in March, but as yet have not updated their criteria. Use of loss of smell and taste as a marker of infection will be a very useful weapon in the COVID-19 fight, especially in countries with emerging pandemics where access to testing will be greatly limited.

References

Prof Claire Hopkins
ENT Dept Guy’s Hospital
London
United kingdom
E-mail: clairehopkins@yahoo.com